Document is current
Any future updates will be listed below
-
Authors
Lee, Yashang
Blount, Katrina Lehmann
Dai, Feng
Thompson, Siobhan
Scher, Jonathan Kaufman
Bitterman, Sherrie
Droher, Madeline
Herzog, Erica L.
Moeckel, Gilbert
Karihaloo, Anil
Dahl, Neera K. https://orcid.org/0000-0001-5809-9961
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK090744)
- License Information
-
More Information
Article History
Received: 1 July 2017
Accepted: 7 February 2018
First Online: 16 February 2018
Compliance with ethical standards
:
: The authors reported the following financial supports: The study was supported by P&F from P30 DK090744 NIDDK Grant (Yale PKD Center), to NKD and AK and 1RO1 HL109233 to EH. This publication was made possible by the Yale University CTSA grant UL1TR000142 from the National Center for Advancing Translational Science (NCATS), NIH. Consultancies: NKD is a PI for one ongoing Otsuka-sponsored study investigating the role of tolvaptan in the treatment of ADPKD and has consulted for Otsuka.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (Yale IRB approval number 1304011838) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted (IRB approval number 2012–10763).
: Informed consent was obtained from all individual participants included in this study.
